Skip to main content
. 2017 Dec 19;9(2):2384–2394. doi: 10.18632/oncotarget.23415

Figure 4. Inhibition or silence of Bcl-2 sensitizes ABC294640 in C33A cells.

Figure 4

C33A cells were treated with ABC294640 (5 μmol/L), together with/out ABT-737 (200 nM) or GDC-0199 (200 nM), cells were further cultured for indicated time, cell growth (MTT assay, (A) and apoptosis (Histone DNA ELISA assay, (B) were tested. mRNA (C) and protein (D) expression of Bcl-2 in stable C33A cells, expressing Bcl-2 shRNA (“shBcl-2-a/-b”, with non-overlapping sequence) or scramble non-sense control shRNA (“c-sh”), were shown; cells were also treated with ABC294640 (5 μmol/L) for indicate time; cell growth (MTT assay, (E) and apoptosis (F and G) were tested. Data were shown as mean (n=5) ± standard deviation (SD). *p<0.05 vs. DMSO (0.1%) cells (A and B). *p<0.05 vs. “c-sh” cells (C-G). Experiments in this figure were repeated three times, and similar results were obtained.